Kiniksa Pharmaceuticals International (KNSA) Change in Accured Expenses (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has 10 years of Change in Accured Expenses data on file, last reported at $25.8 million in Q2 2026.

• Quarterly Change in Accured Expenses rose 96.91% year-over-year to $25.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $48.7 million (up 55.76% YoY) and the FY2025 annual result came in at $37.5 million, down 14.25% from the prior year.
• Change in Accured Expenses advanced to $25.8 million in Q2 2026, from -$5.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $25.8 million in Q2 2026 to a low of -$10.6 million in Q1 2023.
• A 5-year average of $6.4 million and a median of $6.4 million in 2023 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses tumbled 456.87% — and 2023, when it jumped 345.95%.
• Tracing KNSA's Change in Accured Expenses over 5 years: stood at -$3.8 million in 2022, then jumped by 239.44% to $5.3 million in 2023, then jumped by 107.96% to $11.0 million in 2024, then jumped by 78.54% to $19.6 million in 2025, then surged by 31.41% to $25.8 million in 2026.
• The last three Change in Accured Expenses figures came in at $25.8 million (Q2 2026), -$5.0 million (Q1 2026), and $19.6 million (Q4 2025), per Business Quant data.